[{"id":"95501520-56c2-4384-b4db-b35ffc085951","acronym":"REACtiVe-2","url":"https://clinicaltrials.gov/study/NCT05650918","created_at":"2022-12-14T14:58:22.504Z","updated_at":"2024-07-02T16:35:33.672Z","phase":"Phase 1","brief_title":"MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)","source_id_and_acronym":"NCT05650918 - REACtiVe-2","lead_sponsor":"Joachim Aerts, MD PhD","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MesoPher (autologous dendritic cell vaccine) • mitazalimab (ADC-1013)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 05/23/2023","study_completion_date":" 05/23/2023","last_update_posted":"2023-10-12"}]